{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:32:44Z","timestamp":1790609564970,"version":"4.1.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Minks, cats, and some other species of carnivores are susceptible of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and have a high risk of transmitting SARS-CoV-2 to humans. The development of animal vaccines can be an effective measure to protect animals against SARS-CoV-2 and reduce the potential risk of human infection. We previously developed a messenger ribonucleic acid (mRNA) vaccine SYS6006 that has been proven to be an efficient coronavirus disease 2019 (COVID-19) vaccine widely used in humans. Here, we further evaluated the safety and immunogenicity of SYS6006 as an animal COVID-19 vaccine candidate for SARS-CoV-2 susceptible animals or wild animals. SYS6006 was safe and immunogenic in mice and completely protected mice against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. SYS6006 was able to induce neutralizing antibodies against the SARS-CoV-2 wild-type, Delta, and Omicron BA.2 strain on day 7 after prime immunization, and two doses of immunization could enhance the neutralizing antibody responses and produce long-lasting potent antibodies for more than 8 months in minks and cats, blue foxes, and raccoon dogs, while all immunized animals had no abnormal clinical signs during immunization. These results provided here warrant further development of this safe and efficacious mRNA vaccine platform against animal COVID-19.<\/jats:p>","DOI":"10.3389\/fcimb.2024.1468775","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T06:01:04Z","timestamp":1726725664000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and immunogenicity of a SARS-CoV-2 mRNA vaccine (SYS6006) in minks, cats, blue foxes, and raccoon dogs"],"prefix":"10.3389","volume":"14","author":[{"given":"Hong","family":"Huo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinying","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongxun","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoling","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xijun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntao","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41579-022-00841-7","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2215067120","article-title":"White-tailed deer may serve as a wildlife reservoir for nearly extinct SARS-CoV-2 variants of concern","volume":"120","author":"Caserta","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent omicron-containing booster vaccine against Covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3390\/vaccines9060631","article-title":"A veterinary vaccine for SARS-CoV-2: The first COVID-19 vaccine for animals","volume":"9","author":"Chavda","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2285089","article-title":"Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials","volume":"19","author":"Chen","year":"2023","journal-title":"Hum. Vaccines Immunotherapeutics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","article-title":"Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis","volume":"27","author":"Choi","year":"2021","journal-title":"Nat. Med."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106848","article-title":"COVID-19 vaccination in animals: A strategy for combating the global outbreak","volume":"105","author":"Choudhary","year":"2022","journal-title":"Int. J. Surg."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009952","article-title":"An outbreak of SARS-CoV-2 with high mortality in mink (Neovison vison) on multiple Utah farms","volume":"17","author":"Eckstrand","year":"2021","journal-title":"PLoS Pathog."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.47895\/amp.v58i7.7930","article-title":"Efficacy, effectiveness, and safety of COVID-19 vaccine compared to placebo in preventing COVID-19 infection among 12-17 years old: A systematic review","volume":"58","author":"Gregorio","year":"2024","journal-title":"Acta Med. Philipp"},{"key":"B13","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/med.21941","article-title":"Research progress in spike mutations of SARS-CoV-2 variants and vaccine development","volume":"43","author":"He","year":"2023","journal-title":"Medicinal Res. Rev."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29542","article-title":"Long-term immunogenicity and safety of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants who had received two or three doses of inactivated vaccine","volume":"96","author":"Huang","year":"2024","journal-title":"J. Med. Virol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1111\/tbed.14356","article-title":"Transmission dynamics and susceptibility patterns of SARS-CoV-2 in domestic, farmed and wild animals: Sustainable One Health surveillance for conservation and public health to prevent future epidemics and pandemics","volume":"69","author":"Islam","year":"2022","journal-title":"Transboundary Emerging Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.vaccine.2024.01.098","article-title":"Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial","volume":"42","author":"Jin","year":"2024","journal-title":"Vaccine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ajps.2022.05.003","article-title":"mRNA vaccines: Past, present, future","volume":"17","author":"Karam","year":"2022","journal-title":"Asian J. Pharm. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/1473-3099(20)30912-9","article-title":"SARS-CoV-2 and the human-animal interface: outbreaks on mink farms","volume":"21","author":"Koopmans","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1093\/cid\/ciab226","article-title":"Evaluating the long-term efficacy of coronavirus disease 2019 (COVID-19) vaccines","volume":"73","author":"Lin","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"6802","DOI":"10.1038\/s41467-021-27096-9","article-title":"Adaptation, spread and transmission of SARS-CoV-2 in farmed minks and associated humans in the Netherlands","volume":"12","author":"Lu","year":"2021","journal-title":"Nat. Commun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1126\/science.abe5901","article-title":"Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans","volume":"371","author":"Munnink","year":"2021","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.onehlt.2023.100653","article-title":"Data on SARS-CoV-2 events in animals: Mind the gap","volume":"17","author":"Nerpel","year":"2023","journal-title":"One Health"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.4049\/jimmunol.2300378","article-title":"Infection dynamics, pathogenesis, and immunity to SARS-CoV-2 in naturally susceptible animal species","volume":"211","author":"Nooruzzaman","year":"2023","journal-title":"J. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discovery"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.2002083","article-title":"A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson","volume":"18","author":"Patel","year":"2022","journal-title":"Hum. Vaccin Immunother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.medj.2021.12.002","article-title":"Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection","volume":"3","author":"Puranik","year":"2022","journal-title":"Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1111\/tbed.13659","article-title":"First detection and genome sequencing of SARS-CoV-2 in an infected cat in France","volume":"67","author":"Sailleau","year":"2020","journal-title":"Transboundary Emerging Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1126\/science.abb7015","article-title":"Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2","volume":"368","author":"Shi","year":"2020","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1631\/jzus.B2000083","article-title":"An overview of COVID-19","volume":"21","author":"Shi","year":"2020","journal-title":"J. Zhejiang Univ Sci. B"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwaa291","article-title":"Replication, pathogenicity, and transmission of SARS-CoV-2 in minks","volume":"8","author":"Shuai","year":"2021","journal-title":"Natl. Sci. Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.3201\/eid2807.212605","article-title":"Suspected cat-to-human transmission of SARS-CoV-2, Thailand, July-September 2021","volume":"28","author":"Sila","year":"2022","journal-title":"Emerging Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41586-020-2334-5","article-title":"Infection of dogs with SARS-Cov-2","volume":"586","author":"Sit","year":"2020","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1016\/j.vaccine.2014.03.078","article-title":"How advances in immunology provide insight into improving vaccine efficacy","volume":"32","author":"Slifka","year":"2014","journal-title":"Vaccine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.03.005","article-title":"Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5\/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial","volume":"42","author":"Su","year":"2024","journal-title":"Vaccine"},{"key":"B35","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s13238-020-00767-x","article-title":"Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB\/c and C57BL\/6J mice","volume":"11","author":"Wang","year":"2020","journal-title":"Protein Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1196\/annals.1373.029","article-title":"Efficacy of DNA immunization with F and G protein genes of Nipah virus","volume":"1081","author":"Wang","year":"2006","journal-title":"Impact Emerging Zoonotic Dis. Anim. Health"},{"key":"B37","year":"2023","journal-title":"The COVID-19 vaccine tracker and landscape compiles detailed information of each COVID-19 vaccine candidate in development by closely monitoring their progress through the pipeline"},{"key":"B38","unstructured":"Coronavirus disease (COVID-19) Situation Dashboard\n          \n          2024"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1051576","article-title":"A novel mRNA vaccine, SYS6006, against SARS-CoV-2","volume":"13","author":"Xu","year":"2023","journal-title":"Front. Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1080\/22221751.2020.1817796","article-title":"A serological survey of SARS-CoV-2 in cat in Wuhan","volume":"9","author":"Zhang","year":"2020","journal-title":"Emerging Microbes Infections"},{"key":"B41","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28138","article-title":"The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity","volume":"95","author":"Zhou","year":"2023","journal-title":"J. Med. Virol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1468775\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T06:01:06Z","timestamp":1726725666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1468775\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":42,"alternative-id":["10.3389\/fcimb.2024.1468775"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2024.1468775","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"article-number":"1468775"}}